The next-generation portfolio advisor is a fan of diversified investing, which means he’s no fan of the Magnificent ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

The ASX retreated from earlier gains and closed 0.25% lower on Tuesday, following a late-day tumble in pharma giant CSL ...

ASX rises with Nvidia and gold's record high, Trump’s tariffs hit, Albanese talks to Trump, Musk’s OpenAI bid blocked.

Plus: A new non-opioid painkiller, the wave of lawsuits against Trump EOs, a key vote for RFK Jr., a big radiopharma deal and more.

The global selloff is tearing through markets as traders headed for the exit following Trump’s tariff announcements.